Helus Pharma Completes US$50 Million Capital Markets Offering

Helus Pharma, the commercial operating name of Cybin Inc., has completed. an underwritten offering of 10,309,280 common shares at US$4.85 per share, generating aggregate gross proceeds of US$50 million. Completed on June 25, 2026, the offering provides additional capital to advance the company's clinical development pipeline, including HLP003 for major depressive disorder, HLP004 for generalized anxiety disorder and HLP005.

Helus Pharma is focused on developing proprietary novel serotonergic agonists designed to activate serotonin pathways associated with neuroplasticity, with the broader objective of advancing innovative therapeutic approaches for mental health conditions. Net proceeds will also support working capital and general corporate purposes, strengthening the company's financial position as it progresses its development programs.

Advisory Team:

AIRD & BELLIS LLP

Sherri Altshuler

Danny Kharazmi

Sean Green

Meredith McCann

Teddy Nikolaou

Manjit Singh